Lakefront Biotherapeutics NV
LKFTNasdaqHealthcare · Pharmaceutical Preparations · C9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2029-07-01A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
- Phase 3Recruitingreadout ~2039-07Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tang Capital Management LlcActivist (13D)Oct 29, 2025
- Ecor1 Capital, LlcActivist (13D)Jul 28, 2025
- Gilead Sciences, Inc.Activist (13D)Jan 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.6M | 9.4 | +11.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗- 6-KFORM 6-KMay 27, 2026
- 424B3May 8, 2026
- 6-KFORM 6-KMay 6, 2026
- 6-KFORM 6-KApr 29, 2026
- 6-KMar 31, 2026
- 6-KMar 30, 2026
- 20-FMar 26, 2026
- 6-KFORM 6-KMar 24, 2026
- 6-KFORM 6-KMar 17, 2026
- 6-KFORM 6-KMar 10, 2026
- 6-KFORM 6-KMar 6, 2026
- 6-KFORM 6-KMar 5, 2026
- 6-KFORM 6-KMar 4, 2026
- 6-KFORM 6-KFeb 23, 2026
- 6-KFORM 6-KFeb 19, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.